Antiviral Mechanisms and Nucleoside Analogs

Viruses replicate inside host cells using largely host machinery, so antiviral drugs must hit the few steps that are virus-specific. The dominant and historically first strategy is the nucleoside (and nucleotide) analog: a modified building block that the viral or virus-induced polymerase incorporates into nascent nucleic acid, halting or corrupting replication. Other antivirals target virus-encoded enzymes and entry steps.

Definition

Nucleoside analogs are antiviral agents structurally resembling natural nucleosides that, after intracellular phosphorylation, are incorporated by viral or virus-induced polymerases into viral nucleic acid, thereby terminating chain elongation or impairing replication; they are one class within the broader set of antiviral mechanisms that exploit virus-specific steps.

Scope

The topic explains the general logic of antiviral selectivity and focuses on nucleoside and nucleotide analogs as a recurring mechanism, alongside the main other targets (viral proteases, polymerases, neuraminidase, and entry). It uses prominent examples illustratively. It does not give drug-selection, dosing, or treatment recommendations, which lie outside this educational reference.

Core questions

• Why is selective toxicity especially difficult for antivirals?
• How does a nucleoside analog distinguish viral replication from host nucleic-acid synthesis?
• Besides nucleoside analogs, what virus-specific steps do antivirals target?

Key concepts

• Virus dependence on host machinery and the narrow target space
• Nucleoside and nucleotide analogs as chain terminators
• Intracellular phosphorylation and selective activation
• Virus-encoded enzymes as targets (polymerase, protease, neuraminidase)
• Entry and fusion inhibitors
• Prodrug strategies to improve delivery of nucleotide analogs
• Selective toxicity through virus-specific activation

Mechanisms

Many nucleoside analogs depend on selective activation: some are phosphorylated to the active form preferentially by a virus-encoded kinase, so the drug is concentrated as an active chain terminator chiefly in infected cells. Once triphosphorylated, the analog is recognized by the viral polymerase and incorporated into the growing nucleic-acid strand; because it lacks the chemistry needed for the next bond, elongation stops, or replication is otherwise corrupted. Nucleotide analogs supply a phosphate group to bypass the first activation step and are often given as prodrugs to aid cellular delivery. Other antiviral classes act on virus-encoded enzymes (proteases that process viral polyproteins, polymerases, and influenza neuraminidase) or block viral entry and fusion. Across these mechanisms, selectivity comes from targeting a viral protein or a virus-dependent activation step rather than a host process.

Clinical relevance

These mechanisms underlie therapies for HIV, the hepatitis viruses, herpesviruses, and influenza, among others, and understanding them is central to interpreting antiviral trials and resistance reports. The entry is educational reference on how antivirals work and does not recommend or dose any therapy for an individual patient.

Epidemiology

Chronic viral infections such as those caused by HIV and the hepatitis B and C viruses affect very large populations worldwide, and the development of nucleoside analogs and other targeted antivirals has substantially changed the outlook for several of these infections.

History

Antiviral therapy began with nucleoside analogs in the latter twentieth century; Gertrude Elion's work on selectively activated nucleoside analogs was an early milestone. The field expanded through antiretroviral nucleoside analogs and protease inhibitors for HIV, neuraminidase inhibitors for influenza, and later direct-acting agents for hepatitis C, with reviews by De Clercq cataloguing the approved drugs and their targets.

Key figures

• Erik De Clercq
• Gertrude Elion

Seminal works

• deClercq-2016
• deClercq-2006

Frequently asked questions

How can a nucleoside analog harm the virus without poisoning the host's own DNA synthesis?

Selectivity comes from preferential activation or recognition: some analogs are phosphorylated mainly by a virus-encoded enzyme, and many are incorporated far more readily by the viral polymerase than by host polymerases, concentrating the toxic effect on viral replication.

Are all antivirals nucleoside analogs?

No. Nucleoside and nucleotide analogs are a major class, but antivirals also include protease inhibitors, non-nucleoside polymerase inhibitors, neuraminidase inhibitors, and entry/fusion inhibitors, each targeting a different virus-specific step.